The success of Viagra initially fueled a period of growth for pharma, but recent developments present a uncertain scenario for shareholders. Lower-cost competitors are reducing revenue, and persistent litigation add https://brianqyfo630703.collectblogs.com/85831208/the-blue-pill-and-big-pharma-a-volatile-investment